Ibdah Rasheed K, Rawashdeh Sukaina I, Harahsheh Ehab, Almegdadi Abdallah, Al Ksassbeh Abdullah, Alrabadi Nasr
Division of Cardiology, Department of Internal Medicine, Jordan University for Science and Technology, Irbid, Jordan.
Department of Neurology, Mayo Clinic College of Medicine, Arizona, USA.
J Int Soc Prev Community Dent. 2020 Sep 28;10(5):597-604. doi: 10.4103/jispcd.JISPCD_70_20. eCollection 2020 Sep-Oct.
The aim of this study was to describe the attitude and perception toward antiplatelet/anticoagulant agents in patients with cardiovascular diseases among dentists in the northern district of Jordan and to compare the current practice of Jordanian dentists and the recently published guidelines regarding the management of patients taking antiplatelet/anticoagulant drugs before dental procedures.
This is a cross-sectional study conducted on dentists and dental interns working at the dental clinics in northern Jordan, including dental clinics at Jordan University of Science and Technology (JUST) and the private sector. The total sample size comprised of 128 subjects (78 dentists from JUST and 50 private practitioners). The participants were interviewed using a preformed questionnaire to assess their knowledge and perceptions regarding the antiplatelets and the anticoagulant agents.
Approximately 61.5% of participants from JUST university and 20.0% of those in the private sector were aware of the use of clopidogrel ( < 0.0001). Although the overall awareness regarding other antiplatelets such as prasugrel was very low (8.6%), dentists from JUST (12.8%) showed a significantly higher level of awareness compared to the private practitioners (2.0%) ( = 0.049). More than 70% of the participants from JUST and only 46.0% of the private practitioners were aware of the consequences of interrupting treatment with clopidogrel in patients with coronary stents ( = 0.002). Almost both the participants from JUST (25.78%) and the private sector (24.22%) are consulting the cardiologists with similar frequencies before interrupting the treatment with the antiplatelet/anticoagulant agents. Participants who have clinical PhD qualifications are more aware of the recent clinical guidelines and the newest agents compared to others.
The awareness regarding the newest antiplatelet/anticoagulant agents is poor among the dentists in northern Jordan. However, the majority (62.3%) of them realize the consequences of interrupting such treatments in patients with coronary stents. Unfortunately, only a quarter of the dentists are consulting the cardiologists before interrupting the treatment with the antiplatelet agents. Proper education, courses, and workshops should be performed to the dentists to improve their knowledge about this critical issue.
本研究旨在描述约旦北部地区牙医对心血管疾病患者抗血小板/抗凝药物的态度和认知，并比较约旦牙医目前的做法与最近发表的关于牙科手术前服用抗血小板/抗凝药物患者管理的指南。
这是一项横断面研究，对象为在约旦北部牙科诊所工作的牙医和牙科实习生，包括约旦科技大学（JUST）牙科诊所和私营部门诊所。总样本量为128名受试者（78名来自JUST的牙医和50名私人执业者）。使用预先设计的问卷对参与者进行访谈，以评估他们对抗血小板和抗凝药物的知识和认知。
来自JUST大学的参与者中约61.5%以及私营部门参与者中20.0%知晓氯吡格雷的使用（<0.0001）。尽管对其他抗血小板药物如普拉格雷的总体认知度非常低（8.6%），但来自JUST的牙医（12.8%）的认知水平明显高于私人执业者（2.0%）（P = 0.049）。来自JUST的参与者中超过70%以及只有46.0%的私人执业者知晓中断冠状动脉支架置入患者氯吡格雷治疗的后果（P = 0.002）。来自JUST的参与者（25.78%）和私营部门参与者（24.22%）在中断抗血小板/抗凝药物治疗前咨询心脏病专家的频率相近。拥有临床博士资格的参与者比其他人更了解最新的临床指南和最新药物。
约旦北部的牙医对最新抗血小板/抗凝药物的认知较差。然而，他们中的大多数（62.3%）意识到中断冠状动脉支架置入患者此类治疗的后果。不幸的是，只有四分之一的牙医在中断抗血小板药物治疗前咨询心脏病专家。应为牙医开展适当的教育、课程和研讨会，以提高他们对这一关键问题的认识。
